Vaccine targets swine flu as FDA targets fakes

As the first U.S. doses of government-contracted H1N1 swine flu vaccine were produced last week-via egg-less insect cell technology-the FDA reminds the public to be wary of Internet sites and other promotions for products that claim to diagnose, prevent, treat or cure the virus.

Connecticut-based Protein Sciences continues to produce its recombinant influenza vaccine, fulfilling its obligation under a $35-million grant from the U.S. Department of Health and Human Services. If all goes well, the contract could be extended for five years at a sum of $147 million, according to an HHS announcement.

Production involves the extraction of a gene from a flu virus and then its insertion into a Baculovirus, which multiplies quickly. Cells are then purified to become part of a human vaccine. The technique promises quicker vaccine production than is available via traditional egg-based methods, hence the HHS interest in light of pandemic eventuality. 

Separately, the Fort Worth, TX-based Star-Telegram reports that the FDA has identified some 73 fraudulent swine flu products. It's favorite: "the Photon Genie, an ‘electromedicine instrument' said to strengthen the immune system by using ‘life-nourishing photobiotic energy.'"

- read the HHS announcement
- here's an article on the vaccine
- and here's the Star-Telegram article about fraudulent products

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.